Three‐Year Results of Tapering Tumor Necrosis Factor Inhibitor to Withdrawal Compared to Stable Tumor Necrosis Factor Inhibitor Among Patients With Rheumatoid Arthritis in Sustained Remission: A Multicenter Randomized Trial
Authors' conclusion
In contrast to those receiving stable TNFi treatment, a minority of patients with RA in remission tapering TNFi to withdrawal remained flare free over three years. There was no statistically significant difference in radiographic progression between the groups.
Study context
- Population
- Patients with rheumatoid arthritis (RA) in remission for ≥12 months taking stable TNFi therapy80 completed 3-year follow-up
- Participants
- 99 patients
- Comparison
- Tapering TNFi to withdrawal vs continued stable TNFi
- Primary endpoint
- Co-primary: flare-free survival and radiographic progression
- Follow-up
- 3 years
Methodological detailsmulticentre, open-label, non-inferiority
- Multicentre
- Open-label
- Non-inferiority
Primary result
Flare-free survival
HR for flare
9.4
95% CI 3.9–22.8
P < 0.0001
By group
Taperingvs Stable
HR for flare 9.4 (95% CI 3.9–22.8); P < 0.0001
As reported in the abstract
Further findings
| Outcome | Tapering | Stable | Risk difference (95% CI) | P value | |
|---|---|---|---|---|---|
| Co-primary: radiographic progression · 3 years | 15% | 8% | 6.7% (−7.1% to 20.5%) | P = 0.3 | |
| Denominator | 41 | 38 | |||
| −100102030Difference (linear scale) |
Safety
Adverse events
Original publication
Three‐Year Results of Tapering Tumor Necrosis Factor Inhibitor to Withdrawal Compared to Stable Tumor Necrosis Factor Inhibitor Among Patients With Rheumatoid Arthritis in Sustained Remission: A Multicenter Randomized Trial. Arthritis Rheumatol. Published 26 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →